Shares of Regenxbio ( RGNX ) have risen by 190% since I initially uncovered and recommended a position in this gene therapy pioneer in 2016. The stock has appreciated by just 52% since my February 2018 update piece . With the recently announced acquisition of collaboration partner Auden...

PHILADELPHIA, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. continues to investigate potential securities claims on behalf of investors of Adverum Biotechnologies (“Adverum” or the “Company”) ( NasdaqGS: ADVM ) concerning possible violations of the feder...

This has been a banner year for three biotech stocks and their shareholders. All of them have soared in response to promising clinical trial results for some very different experimental therapies. If you're not sure why these stocks are among the biotech industry's top performers, let's review ...